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MicroRNAs (miRNAs) play a prominent role in gastric cancer (GC) initiation and progression. In this
study, we found that miR-374a expression was up-regulated in human GC cell lines and tissues.
Inhibition of miR-374a suppressed GC cell proliferation, migration and invasion in vitro and slowed
tumor growth in vivo. SRC kinase signaling inhibitor 1 (SRCIN1) was identiﬁed as a direct target of
miR-374a. Silencing of SRCIN1 signiﬁcantly enhanced cell proliferation, migration and invasion,
whereas SRCIN1 reintroduction partially abrogated the oncogenic effects of miR-374a. Taken
together, these ﬁndings suggest that miR-374a functions as a candidate oncogene in GC by directly
targeting SRCIN1. miR-374a may therefore be useful as a promising therapeutic target for malignant
GC.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer (GC) is the fourth most common human cancer
and the second most prevalent cause of cancer-related mortality
in the world [1]. It is estimated that approximately 1 million
new cases of GC are diagnosed per year worldwide [2]. Although
there have been recent advances in surgery and chemotherapy,
the prognosis for GC remains poor, with an overall 5-year survival
rate below 30% [3,4]. Thus, it is of great signiﬁcance to further elu-
cidate the molecular mechanisms of GC and look for new therapeu-
tic targets for this disease [5].
MicroRNAs (miRNAs) are a class of small non-coding, endogen-
ous, single-stranded RNA with 21–23 nucleotides, which regulate
gene expression by inﬂuencing post-transcriptional processing or
mRNA degradation [6,7]. miRNAs play important roles in a range
of biological processes such as cell proliferation, migration and
invasion [8]. Accumulating evidence shows that miRNAs also have
signiﬁcant regulatory functions in various tumors including GC
[9,10]. For example, miR-27a acts as an oncogene, and promotes
cell proliferation by targeting prohibition in gastric adenocarci-
noma [11]. miR-423-5p elevates GC cell proliferation and sup-
presses cell migration and invasion by repressing trefoil factor 1[12]. On the other hand, miR-126 is down-regulated in GC cells
and inhibits cell growth in vitro and in vivo, reduces the capabil-
ities of migration and invasion, and increases apoptosis though
Crk [13]. Therefore, it is important to explore the roles of miRNAs
in the tumor biology of GC.
MicroRNA microarray results have shown that miR-374a
expression is signiﬁcantly up-regulated in GC tissues compared
with adjacent normal tissues [14]. The expression of miR-374a
was previously reported to be elevated in osteosarcoma cell lines
and in colon cancer [15,16]. Functional assays revealed that miR-
374a directly targets Wnt5a, and regulates the proliferation, geﬁti-
nib-induced apoptosis, epithelial-to-mesenchymal transition
(EMT), migration and invasion of non-small cell lung cancer
in vitro and in vivo [17]. Furthermore, ectopic expression of miR-
374a activates Wnt/b-catenin signaling to promote breast cancer
EMT and metastasis in vitro and in vivo by suppressing WIF1, PTEN
or WNT5A expression [18]. However, the exact functions and pre-
cise molecular mechanisms of miR-374a in GC progression remain
undeﬁned.
In this study, up-regulation of miR-374a in GC cells and tissues
was conﬁrmed by real-time PCR. Further investigation demon-
strated that miR-374a inhibition could repress GC cell prolifera-
tion, migration and invasion, and attenuate the tumorigenic
ability of GC cells in animal models. We experimentally conﬁrmed
that miR-374a targets the 30UTR of SRC kinase signaling inhibitor 1
(SRCIN1). Knockdown of SRCIN1 exerted opposite effects of
miR-374a inhibition, while reintroduction of SRCIN1 partially
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tion of GC cells. Thus, our results revealed that miR-374a is an
oncogene and a potential therapeutic target of GC.
2. Materials and methods
2.1. Cells and clinical tissues
GC cell lines MKN-45, HGC-27, BGC-823, and SGC-7901 and the
immortalized normal gastric epithelial cell line GES-1 were
obtained from the American Type Culture Collection (ATCC;
Manassas, VA). All cells were cultured in RPMI 1640 medium
(GIBCO, Carlsbad, CA) supplemented with 10% FBS and 1% penicil-
lin/streptomycin at 37 C in 5% CO2. Human GC tissues and adja-
cent non-cancerous tissues were collected from 18 GC patients
who underwent surgical resection at the Shanghai Changzheng
Hospital. All materials were collected after written informed con-
sent was obtained, and this study was approved by the Ethics Com-
mittee of Changzheng Hospital.
2.2. RNA extraction and real-time PCR
Total RNA was extracted from tissue samples and cell lines
using Trizol reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. The concentration and quality of total
RNA were assessed via spectrophotometric and electrophoretic
assay. First-strand cDNA was synthesized using the SuperScript
III ﬁrst-strand synthesis system (Invitrogen). Real-time PCR was
carried out in the ABI PRISM 7300 system (Applied Biosystems,
Foster City, CA) using the SYBR Premix Ex Taq™ (TaKaRa, Dalian,
China). Relative expression levels of miR-374a and SRCIN1 were
calculated by the 2DDCT method after normalization with refer-
ence to expression of U6 and b-actin. All reactions were carried
out in triplicate.
2.3. Vectors and cell transfection
The wild-type 30UTR of SRCIN1 containing the putative miR-
374a target site was ampliﬁed and cloned into the pGL3-control
luciferase reporter vector (Promega, Madison, WI). The mutant
constructs were generated using a QuickChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA). The coding sequence of
SRCIN1 was ampliﬁed by PCR and inserted into the pcDNA3.1(+)
vector (Invitrogen). All constructs were ﬁnally conﬁrmed by DNA
sequencing. AgomiR-374a, antagomiR-374a and si-SRCIN1 were
obtained from RiboBio (Guangzhou, China) and transfectedFig. 1. miR-374a is up-regulated in human GC cell lines and tissues. (A) Relative expressi
27, BGC-823 and SGC-7901) and the immortalized normal gastric epithelial cell line (GES
their adjacent non-cancerous tissues. Each sample was analyzed in triplicate and normaaccording to the manufacturer’s instructions. Cells were trans-
fected with vectors using Lipofectamine 2000 reagent (Invitrogen).
2.4. Cell proliferation assay and colony formation assay
Cell proliferation was assayed using the Cell Counting Kit-8
(CCK-8). Cells (1.5  103) were plated into 96-well plates and cul-
tured for 1, 2, 3 or 4 days, after which 10 ll CCK-8 was added to
each well, and cells were incubated for a further 2 h at 37 C. The
absorbance was measured at a wavelength of 450 nm. For the col-
ony formation assay, cells were seeded onto a six-well plate at a
density of 500 cells per well after transfection. Approximately
10 days later, the colonies were stained with 1% crystal violet for
5 min after ﬁxation with methanol for 10 min, and the number of
colonies was counted.
2.5. Cell cycle and apoptosis assays
Transfected cells (1  106) were harvested and washed in cold
PBS, followed by ﬁxation in 70% ice-cold ethanol for 30 min. After
washing, cells were pelleted by centrifugation using a chilled cen-
trifuge and resuspended in 0.8 ml of PBS with 40 lg of propidium
iodide and 0.1 lg of RNase A for 30 min at 37 C. Samples were
analyzed for DNA content using a FACSCaliber ﬂow cytometer
(BD Bioscience, San Jose, CA). For apoptosis assay, transfected cells
were stained with AnnexinV/PI Apoptosis Detection kit (Promega)
according to the manufacturer’s protocol. Apoptotic cells were ana-
lyzed using ﬂow cytometry.
2.6. Cell migration and invasion assays
BGC-823-antagomiR-374a or SGC-7901-antagomiR-374a cells
(1  105 cells/well) were plated on the top side of transwell cham-
bers coated without or with Matrigel (BD Bioscience). Medium
containing 20% FBS in the lower chambers functioned as the
chemo-attractant. After 24 h, the cells adhering to the lower side
of the membrane were ﬁxed, stained with crystal violet and
counted under a microscope (Olympus Corp., Tokyo, Japan).
2.7. Xenograft model in nude mice
SGC-7901-antagomiR-374a cells (2  106) in 0.2 ml serum-free
mediumwere subcutaneously inoculated into the left ﬂank of nude
mice (n = 4). Tumor volume (V) was assessed every week by mea-
suring the length (A) and the width (B) using a slide caliper, and
calculated by the formula: V = 0.5  A  B2. After 5 weeks, all miceon of miR-374a was examined by real-time PCR in four GC cell lines (MKN-45, HGC-
-1). (B) Real-time PCR analysis of miR-374a expression in 18 pairs of GC tissues and
lized to U6, ⁄P < 0.05.
Fig. 2. miR-374a inhibition suppresses GC cell proliferation, migration and invasion. (A) SGC-7901 cells were transfected with antagomiR-NC or antagomiR-374a for 48 h, and
cell viability was analyzed by CCK-8 assay. (B) Colony formation assay. (C, D) Flow cytometric analysis of cell cycle and apoptosis of the transfected cells. (E) Transwell
migration assay was used to evaluate cell migration. (F) Transwell invasion assay, ⁄P < 0.05.
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measured and recorded. Tumor tissues were stored for further
analysis.
2.8. Immunohistochemical analysis
Tumor tissues were ﬁxed in 10% neutral buffered formalin,
embedded with parafﬁn, and sliced into 4-lm sections. After
mounting on slides the parafﬁn sections were baked, deparafﬁ-
nized and dehydrated, antigen retrieval was carried out by boiling
in 0.1 M citrate buffer (pH 6.0) for 15 min. The slides were incu-
bated in 3% H2O2 for 10 min to suppress endogenous peroxidase
activity, then sections were blocked with 10% goat serum in PBS
for 30 min and incubated with rabbit anti-Ki67 polyclonalantibody (Abcam, Cambridge, UK) for 1 h at room temperature.
Finally, the percentage of Ki67 positive cells were calculated under
a microscope and photos were taken for analysis.2.9. Luciferase assay
pGL3-SRCIN1-30UTR-WT or pGL3-SRCIN1-30UTR-MUT con-
structs were transfected into HEK293T cells, along with agomiR-
374a or agomiR-NC and pRL-TK vector (Promega). Forty-eight
hours post-transfection, luciferase activities were assayed using
the Dual Luciferase Reporter Assay kit (Promega) according to
the manufacturer’s protocol. Renilla luciferase activity was used
for endogenous normalization.
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Total proteins were extracted and measured using the BCA pro-
tein assay kit (Thermo Scientiﬁc, Rockford, IL). Equal amounts of
protein (30 lg) were loaded, separated by 8% SDS–PAGE, and
transferred to PVDF membranes (Millipore, Danvers, MA). After
blocking with 5% non-fat milk in TBS, membranes were probed
with primary antibodies against SRCIN1 (Cell Signaling Technol-
ogy, Danvers, MA) or GAPDH (Santa Cruz Biotechnology, Santa
Cruz, CA), followed by peroxidase-conjugated secondary antibo-
dies (Santa Cruz Biotechnology). Bands were visualized using
enhanced chemiluminescence (Thermo Scientiﬁc).
2.11. Statistical analysis
Results are expressed as the mean ± S.D. The differences
between two groups were assessed by Student’s t-test. The rela-
tionship between miR-374a and SRCIN1 expression was explored
by Spearman’s correlation. P < 0.05 was considered signiﬁcant.
3. Results
3.1. miR-374a expression is up-regulated in human GC cell lines and
tissues
We initially examined the expression level of miR-374a in four
GC cell lines (MKN-45, HGC-27, BGC-823 and SGC-7901) and the
immortalized normal gastric epithelial cell line GES-1. As shown
in Fig. 1A, the expression level of miR-374a was signiﬁcantly
increased in GC cell lines compared with GES-1. Real-time PCR
was then conducted to analyze 18 pairs of GC tissues and theirFig. 3. Inhibition of miR-374a suppresses tumorigenicity in vivo. SGC-7901 cells transfec
mice. After 35 days, the nude mice were killed. Images of representative tumors are sho
calculated each week after injection. (C) Average weight of tumors at the end of the
(E) Real-time PCR analysis of the expression of miR-374a and SRCIN1 mRNA in xenogramatched normal tissues. The result showed that miR-374a expres-
sion was signiﬁcantly higher in GC tissues than in their paired cor-
responding non-cancerous tissues. These results provide strong
evidence that the expression of miR-374a is elevated in GC cell
lines and tissues.
3.2. miR-374a inhibition suppresses GC cell proliferation, migration
and invasion
miR-374a expression was increased in GC cell lines and tissues,
which prompted us to investigate the biological signiﬁcance of
miR-374a in tumorigenesis. As an initial step, we selected
SGC-7901 and BGC-823 cells for transfection experiments. After
SGC-7901 and BGC-823 cells were transfected with miR-374a spe-
ciﬁc inhibitor antagomiR-374a or antagomiR-NC for 48 h, the CCK-
8 assay was used to evaluate their growth rate. The result showed
that cell viability was remarkably reduced upon antagomiR-374a
treatment (Fig. 2A and S1A). Accordingly, the colony formation rate
of these cells transfected with antagomiR-374a was signiﬁcantly
decreased compared to the control group (Fig. 2B and S1B). We also
analyzed cell-cycle progression by ﬂow cytometric analysis and
found that SGC-7901-antagomiR-374a and BGC-823-antagomiR-
374a cells showed a decrease in the S-phase peak and a dramatic
cell cycle arrest at the G1/G0 phase compared to negative controls
(Fig. 2C and S1C). In addition, the rate of apoptosis was signiﬁ-
cantly higher in antagomiR-374a-transfected cells (Fig. 2D and
S1D). Moreover, transwell assays showed that antagomiR-374a
signiﬁcantly suppressed the migration and invasion of SGC-7901
and BGC-823 cells (Fig. 2E, F and S1E). Collectively, these data sug-
gest that miR-374a inhibition reduces the proliferation, migration
and invasion of GC cells.ted with antagomiR-NC or antagomiR-374a were injected subcutaneously into nude
wn in (A). (B) Growth curve of tumors in nude mice, the volume of each tumor was
experiment. (D) Percentage of positive cells by IHC for Ki-67 in tumor tissues.
ft tumor tissues, ⁄P < 0.05.
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We next examined whether miR-374a inhibition could affect
the growth of gastric tumors in vivo. SGC-7901-antagomiR-374a
or SGC-7901-antagomiR-NC cells were injected subcutaneously
into nude mice. Five weeks after injection, SGC-7901-antagomiR-
374a cells formed smaller tumors than control cells (Fig. 3A and
B). The mean weight of tumors transfected with miR-374a inhibi-
tor was markedly lower than that of the negative control group
(Fig. 3C). Furthermore, IHC conﬁrmed that the percentage of
Ki-67 positive cells in the tumors with miR-374a inhibitor mark-
edly decreased compared with that in the negative control group
(Fig. 3D). Hence, a decreased proliferation rate caused by miR-
374a inhibition is responsible for tumor suppression in vivo.
3.4. SRCIN1is a direct target of miR-374a
As miRNAs often regulate the expression of target genes, we
searched for putative candidate targets of miR-374a using different
bioinformatics algorithms such as TargetScan, Microrna and PicTar.
Among the predicted miR-374a targets, SRCIN1, an inhibitor of Src
activity and signaling, was chosen for further experimental veriﬁ-
cation. The 30UTR of SRCIN1 mRNA contains a complementary site
for the seed region of miR-374a (Fig. 4A). To investigate whether
miR-374a directly interacts with SRCIN1, we constructed Luc-
SRCIN1-30UTR-wild-type (WT) and its 30UTR mutant (MUT)
plasmids. Luciferase reporter assays showed that agomiR-374a
suppressed transcriptional activity of the Luc-SRCIN1-30UTR-WTFig. 4. SRCIN1 is a direct target of miR-374a. (A) Wild-type and mutant sequences of th
performed after HEK293T cells were transfected with luciferase reporter plasmids contai
NC. Renilla luciferase activity was used for endogenous normalization. The mRNA (C) an
agomiR-374a or antagomiR-374a were analyzed by real-time PCR andWestern blot, respe
level was inversely correlated with SRCIN1 mRNA level in GC tissues, ⁄P < 0.05.reporter by more than 50% compared with agomiR-NC, whereas
the SRCIN1-30UTR-MUT, in which the putative miR-374a binding
site had been mutated, was refractile to the inhibition (Fig. 4B).
We also conﬁrmed that SRCIN1 mRNA and protein expression
was decreased by the introduction of agomiR-374a, whereas it
was signiﬁcantly elevated by the transfection of antagomiR-374a
in SGC-7901 and BGC-823 cells (Fig. 4C and D). Moreover, we
examined the endogenous mRNA level of SRCIN1 in 18 pairs of
GC tissues and matched non-tumor tissues, and found an inverse
correlation between miR-374a and SRCIN1 mRNA levels (Fig. 4E).
Real-time PCR analysis of the xenograft subcutaneous tumors also
conﬁrmed reduced miR-374a with enhanced SRCIN1 mRNA in
antagomiR-374a-treated tumors (Fig. 3E). Taken together, these
results suggest that miR-374a directly targets SRCIN1 and inhibits
its expression.
3.5. Downregulation of SRCIN1 promotes GC cell proliferation,
migration and invasion
It has been reported that SRCIN1 is essential for the regulation
of cell proliferation and motility [12]. However, the effects of
SRCIN1 on GC cells have not been characterized. To explore the
roles of SRCIN1, we transfected SGC-7901 cells with speciﬁc siR-
NAs against SRCIN1, and Western blotting analysis revealed that
SRCIN1 expression was signiﬁcantly reduced after si-SRCIN1 trans-
fection (Fig. 5A). Functional assays showed that si-SRCIN1 could
promote GC cell proliferation, migration and invasion (Fig. 5B
and C), suggesting a tumor suppressor role of SRCIN1 in GC cells.e putative miR-374a target sequences of SRCIN1 30UTR. (B) Luciferase assays were
ning SRCIN1-30UTR-WT or SRCIN1-30UTR-MUT, along with agomiR-374a or agomiR-
d protein (D) expression of SRCIN1 in SGC-7901 and BGC-823 cells transfected with
ctively. (E) Spearman’s correlation analysis demonstrated that miR-374a expression
Fig. 5. Suppression of SRCIN1 promotes GC cell proliferation, migration and invasion while restoration of SRCIN1 reverses the biological phenomena induced by miR-374a.
(A) Western blotting was performed to detect the protein level of SRCIN1 after transfection with si-SRCIN1 or vector into SGC-7901 cells. Representative histograms depict
cell proliferation (B), migration and invasion (C). (D) The protein level of SRCIN1 in SGC-7901 cells after transfection with agomiR-NC, agomiR-374a or agomiR-374a and
SRCIN1 vector. (E) Cell proliferation. (F) Cell migration and invasion, ⁄P < 0.05.
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We further evaluated whether reintroduction of SRCIN1 could
reverse the effects of miR-374a. SGC-7901 cells were transfected
with agomiR-NC, agomiR-374a, or cotransfected with agomiR-
374a and SRCIN1 vector (lacking 30UTR) (Fig. 5D). As shown in
Fig. 5E and F, overexpression of miR-374a signiﬁcantly promoted
cell proliferation, migration and invasion, whereas reintroduction
of SRCIN1 abrogated miR-374a-dependent effects. These data sug-
gest that SRCIN1 is a functional mediator for miR-374a in GC cells.
4. Discussion
miRNAs serve as crucial regulators of gene expression, regulat-
ing cellular physiology and development [19]. Accumulating evi-
dence has demonstrated that aberrant expression of miRNAs is
related to tumorigenesis, progression and prognosis of various
types of human cancers including GC [20–22], and that miRNAs
can bind directly to their target genes to regulate cellular processes
in GC. For example, miR-196a/-196b expression is up-regulated in
GC tissues. Its expression inversely regulates GC invasion, migra-
tion and lung metastasis [23]. miR-296-5p increases GC prolifera-
tion and decreases GC apoptosis, and inhibition of both processes
could provide beneﬁcial GC treatments [24]. Thus, identifying
and elucidating the exact roles and underlying mechanisms of
miRNAs in GC may help us to understand the etiology and patho-
genesis of GC and provide novel therapeutic targets. In this study,
we focus on the potential oncogene miR-374a.We ﬁrst conﬁrmed that miR-374a expression is markedly
higher in GC cell lines and tissues than in GES-1 and normal gastric
tissues. At the cytological level, inhibition of miR-374a suppresses
proliferation, invasion and migration of GC cells and markedly
reduces tumorigenesis in vivo. Furthermore, luciferase reporter
assays show that miR-374a directly targets SRCIN1 though its
30UTR.
SRCIN1, which is also known as p140CAP (p140 cas-associated
protein), contains two coiled-coil domains, two proline-rich
regions and two regions of highly charged amino acids [25,26].
According to the characteristic domain structure, SRCIN1 is
thought to act as an adaptor protein [27]. Recently, SRCIN1 has
been shown to participate in tumor progression, as an inverse reg-
ulator of integrin and growth factor-dependent tumor cell proper-
ties [25,28]. Screening of mammary breast cancers showed a
positive interaction between the expression of SRCIN1 and malig-
nancy [29]. SRCIN1 was shown to suppress the spreading, migra-
tion and invasion of breast cancer cells [30]. Furthermore,
overexpression of SRCIN1 has also been shown to reverse the onco-
genic effects of miR-150 on proliferation, migration and invasion in
lung cancer cells [31]. These results suggest that SRCIN1 functions
as a tumor suppressor gene and may slow tumor progression.
However, the way in which SRCIN1 acts at the molecular and cel-
lular levels in GC still remains unclear. In this study, we found that
silencing of SRCIN1 promotes GC cell proliferation, invasion and
migration. Reintroduction of SRCIN1 is able to abrogate the onco-
genic effects of miR-374a. Furthermore, SRCIN1 expression inver-
sely correlates with miR-374a in clinical samples. These results
suggest that SRCIN1 is a functional mediator for miR-374a in GC.
X. Xu et al. / FEBS Letters 589 (2015) 407–413 413In conclusion, we have shown for the ﬁrst time that miR-374a
promotes GC cell proliferation, migration and invasion by directly
targeting SRCIN1. This study therefore has provided a novel pro-
mising therapeutic target for GC.
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